Staff members from more than 40 CARSTAR locations across Canada joined in on the 21st annual Walk to Make Cystic Fibrosis History. 

“Today was truly incredible!” franchise staff wrote on its social media pages. “... We are beyond proud to stand side by side with our CF families and be part of something so meaningful. Together, we’re creating a future full of hope and progress.”

Thousands of other Canadians also joined in on the nationwide event, which was organized by Cystic Fibrosis Canada to raise funds and awareness for the genetic disorder. The annual event has become Canada's largest national fundraiser for CF, raising over $48 million. This year's event continued to build on that legacy, bringing together individuals, families and communities in a unified effort to combat the disease.

Cystic fibrosis is a genetic disorder that primarily affects the respiratory and digestive systems. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator, which regulates the movement of salt and water in and out of cells. When the CFTR gene is faulty, it leads to the production of thick mucus in various organs, especially the lungs and pancreas. This abnormal mucus can clog airways and trap bacteria, resulting in chronic lung infections, persistent coughing and difficulty breathing.

In addition to respiratory complications, cystic fibrosis impacts digestion. Mucus can block pancreatic enzymes from reaching the intestines, which hinders the body’s ability to break down and absorb nutrients. As a result, individuals with CF often experience poor growth, weight loss and vitamin deficiencies. Managing the digestive symptoms of CF typically involves a high-calorie diet, enzyme supplements and regular monitoring by specialized care teams.

Cystic fibrosis is a progressive, life-shortening disease, though advances in treatment have significantly improved life expectancy and quality of life in recent decades. There is no known cure, but therapies such as airway clearance techniques, inhaled medications and newer CFTR modulator drugs can target the underlying cause of the disease in some individuals. Regular monitoring, multidisciplinary care and community support play essential roles in helping those with CF lead longer and more active lives.